Stereotactic radiotherapy for ultracentral lung tumours
Cancer Radiother. 2023 Jul 27:S1278-3218(23)00130-0. doi: 10.1016/j.canrad.2023.06.021. Online ahead of print.ABSTRACTUltracentral (UC) lung lesions are generally defined by the presence of the tumour or the Planning Target Volume (PTV) abutting proximal bronchial tree (PBT) or the esophagus. Initial reports rose awareness regarding the potential toxicity of stereotactic body radiotherapy (SBRT) when delivered to UC lesions. Major concerns include necrosis, stenosis, and bleeding of the PBT. Technological improvements now enable the delivery of more accurate treatments, possibly redefining the historical "no-fly zone". In ...
Source: Cancer Radiotherapie - July 29, 2023 Category: Cancer & Oncology Authors: V Bourbonne S Thureau O Pradier D Antoni F Lucia Source Type: research
The morbidity and mortality review meetings in radiotherapy departments: Procedure, implementation and prospects of the "Proust" French national project
Cancer Radiother. 2023 Jul 26:S1278-3218(23)00132-4. doi: 10.1016/j.canrad.2023.06.018. Online ahead of print.ABSTRACTRadiation-induced acute and late toxicity depends on several parameters. The type, severity and duration of morbidity are mainly related to irradiated volume, total dose and its fractionation and the intrinsic radiosensitivity of the patients. The follow-up of these toxicities is essential. However, unlike many specialties, morbidity and mortality reviews procedures are not developed as part of quality governance programs in radiation therapy departments for the monitoring of toxicity which sometimes hinder...
Source: Cancer Radiotherapie - July 28, 2023 Category: Cancer & Oncology Authors: Y Belkacemi K Debbi C Besnard N Grellier G Fonteneau L Colson-Durand D Lerouge C Durdux F Campana P Pons I Flandin D Pasquier R de Crevoisier T Wachter S Thureau G No ël L Conzague-Casabianca A Petit S Supiot D Azria Source Type: research
Place of radiotherapy for treatment of metastatic cervical, vaginal and endometrial uterine cancer
Cancer Radiother. 2023 Jul 26:S1278-3218(23)00125-7. doi: 10.1016/j.canrad.2023.06.012. Online ahead of print.ABSTRACTBeyond classical palliative-intent irradiation schemes, there are increasing data suggesting a benefit for intensive locoregional treatments in metastatic gynecological cancers. Such approach aims at avoiding local symptoms related to tumor progression, but may also improve survival outcome by shrinking tumor burden to a microscopic state. This strategy is rarely considered upfront (in highly selected patients with very limited oligometastatic disease), but rather after systemic treatment. In case of tumor ...
Source: Cancer Radiotherapie - July 28, 2023 Category: Cancer & Oncology Authors: A Escande J Leblanc J-M Hannoun-Levi S Renard A Ducassou C Hennequin C Chargari Source Type: research
The morbidity and mortality review meetings in radiotherapy departments: Procedure, implementation and prospects of the "Proust" French national project
Cancer Radiother. 2023 Jul 26:S1278-3218(23)00132-4. doi: 10.1016/j.canrad.2023.06.018. Online ahead of print.ABSTRACTRadiation-induced acute and late toxicity depends on several parameters. The type, severity and duration of morbidity are mainly related to irradiated volume, total dose and its fractionation and the intrinsic radiosensitivity of the patients. The follow-up of these toxicities is essential. However, unlike many specialties, morbidity and mortality reviews procedures are not developed as part of quality governance programs in radiation therapy departments for the monitoring of toxicity which sometimes hinder...
Source: Cancer Radiotherapie - July 28, 2023 Category: Cancer & Oncology Authors: Y Belkacemi K Debbi C Besnard N Grellier G Fonteneau L Colson-Durand D Lerouge C Durdux F Campana P Pons I Flandin D Pasquier R de Crevoisier T Wachter S Thureau G No ël L Conzague-Casabianca A Petit S Supiot D Azria Source Type: research
Place of radiotherapy for treatment of metastatic cervical, vaginal and endometrial uterine cancer
Cancer Radiother. 2023 Jul 26:S1278-3218(23)00125-7. doi: 10.1016/j.canrad.2023.06.012. Online ahead of print.ABSTRACTBeyond classical palliative-intent irradiation schemes, there are increasing data suggesting a benefit for intensive locoregional treatments in metastatic gynecological cancers. Such approach aims at avoiding local symptoms related to tumor progression, but may also improve survival outcome by shrinking tumor burden to a microscopic state. This strategy is rarely considered upfront (in highly selected patients with very limited oligometastatic disease), but rather after systemic treatment. In case of tumor ...
Source: Cancer Radiotherapie - July 28, 2023 Category: Cancer & Oncology Authors: A Escande J Leblanc J-M Hannoun-Levi S Renard A Ducassou C Hennequin C Chargari Source Type: research
Radiotherapy in the management of rare gastrointestinal cancers: A systematic review
In conclusion, radiotherapy is not an uncommon indication in this context. A multidisciplinary approach is needed for better management of digestive rare cancers.PMID:37500390 | DOI:10.1016/j.canrad.2023.06.010 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - July 27, 2023 Category: Cancer & Oncology Authors: F Z Bellefkih N Benchakroun I Lalya B Amaoui H El Kacemi A Acharki M El Hfid A El Mazghi T Chekrine Z Bouchbika H Jouhadi S Sahraoui N Tawfiq M Michalet Source Type: research
Contribution of chemotherapy in immunoradiotherapy combinations
Cancer Radiother. 2023 Jul 24:S1278-3218(23)00129-4. doi: 10.1016/j.canrad.2023.06.015. Online ahead of print.ABSTRACTSeveral preclinical data have suggested the ability of radiation therapy to modulate the intrinsic immunogenicity of cancer cells and the tumor microenvironment, with the aim of increasing responses to checkpoint inhibitors. Early results showing a restoration of checkpoint inhibitors response in patients following irradiation have generated a lot of enthusiasm around radiation therapy beyond its usual role in local disease control. Prospective clinical trials evaluating immunoradiotherapy combinations have...
Source: Cancer Radiotherapie - July 26, 2023 Category: Cancer & Oncology Authors: Y Xie B Lecoester J Boustani Source Type: research
Contribution of chemotherapy in immunoradiotherapy combinations
Cancer Radiother. 2023 Jul 24:S1278-3218(23)00129-4. doi: 10.1016/j.canrad.2023.06.015. Online ahead of print.ABSTRACTSeveral preclinical data have suggested the ability of radiation therapy to modulate the intrinsic immunogenicity of cancer cells and the tumor microenvironment, with the aim of increasing responses to checkpoint inhibitors. Early results showing a restoration of checkpoint inhibitors response in patients following irradiation have generated a lot of enthusiasm around radiation therapy beyond its usual role in local disease control. Prospective clinical trials evaluating immunoradiotherapy combinations have...
Source: Cancer Radiotherapie - July 26, 2023 Category: Cancer & Oncology Authors: Y Xie B Lecoester J Boustani Source Type: research
A dosimetric comparative study following RTOG and ESTRO contouring guidelines for breast radiation therapy
CONCLUSION: Unless having higher doses to thyroid when the RTOG guideline was adopted, the doses to other organs-at-risk (OAR) were similar between the two considering guidelines. Moreover, except for higher EUD, TCP, and CI for VMAT when the ESTRO guideline was used, no other significant differences were obtained between dosimetric parameters of target volumes considering the RT techniques and contouring guidelines.PMID:37482461 | DOI:10.1016/j.canrad.2023.06.003 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - July 23, 2023 Category: Cancer & Oncology Authors: Sh Anjidani Z Siavashpour M Houshyari M Haghgoo M Nazarnejad F Zayeri S Alireza Javadinia Source Type: research
The quality manager in radiation therapy: Evolution of the role, presentation of a French national Survey
CONCLUSION: The hierarchical position of the quality manager needs to be better defined, as does the notion of authority. The time and resources allocated to the function and to the quality/safety approach also need to be adapted, as these are the main factors of tension identified by the survey. The publication of ASN Decision 2019-DC-660 has extended the scope of the quality manager to include imaging in several centers.PMID:37482462 | DOI:10.1016/j.canrad.2023.06.009 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - July 23, 2023 Category: Cancer & Oncology Authors: G Brusadin S Cucchiaro S Nardin É Leroy Source Type: research
RadioTransNet, Radiotherapy Translational and Preclinical Research Network: Results from the dedicated French cancer institute (INCa) call for projects
CONCLUSION: RadioTransNet project has been launched in 2018, supported by INCa, in order to structure and promote preclinical research in oncology radiotherapy and to favor collaboration between the actors of this research. INCa relied on RadioTransNet initiatives and activities, resulting in the opening of dedicated call for projects. Beyond its first main goals, RadioTransNet network is able to help to fund the human and technical resources necessary to conduct optimal translational and preclinical research in radiation oncology.PMID:37482463 | DOI:10.1016/j.canrad.2023.06.019 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - July 23, 2023 Category: Cancer & Oncology Authors: É Bayart R De Crevoisier A Laprie F Milliat Y Prezado V Marchesi P Maingon Source Type: research
Prediction of toxicity outcomes following radiotherapy using deep learning-based models: A systematic review
CONCLUSION: Deep learning techniques are able to produce a consistent performance for toxicity prediction. Future research using large and diverse datasets and standardization of the study methodologies are required to improve the consistency of the research output.PMID:37482464 | DOI:10.1016/j.canrad.2023.05.001 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - July 23, 2023 Category: Cancer & Oncology Authors: D Tan N F Mohd Nasir H Abdul Manan N Yahya Source Type: research
Stereotactic radiotherapy in Morocco : Inventory and technological compatibility with the minimum requirements of international recommendations of good practice
Cancer Radiother. 2023 Jul 21:S1278-3218(23)00120-8. doi: 10.1016/j.canrad.2023.06.007. Online ahead of print.NO ABSTRACTPMID:37482465 | DOI:10.1016/j.canrad.2023.06.007 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - July 23, 2023 Category: Cancer & Oncology Authors: I Lalya N Benchakroun H Sifat H El Kacemi None B Amaoui M El Hfid S Sahraoui S A El Mazghi A Tahri A Benider A Acharki Source Type: research
A dosimetric comparative study following RTOG and ESTRO contouring guidelines for breast radiation therapy
CONCLUSION: Unless having higher doses to thyroid when the RTOG guideline was adopted, the doses to other organs-at-risk (OAR) were similar between the two considering guidelines. Moreover, except for higher EUD, TCP, and CI for VMAT when the ESTRO guideline was used, no other significant differences were obtained between dosimetric parameters of target volumes considering the RT techniques and contouring guidelines.PMID:37482461 | DOI:10.1016/j.canrad.2023.06.003 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - July 23, 2023 Category: Cancer & Oncology Authors: Sh Anjidani Z Siavashpour M Houshyari M Haghgoo M Nazarnejad F Zayeri S Alireza Javadinia Source Type: research
The quality manager in radiation therapy: Evolution of the role, presentation of a French national Survey
CONCLUSION: The hierarchical position of the quality manager needs to be better defined, as does the notion of authority. The time and resources allocated to the function and to the quality/safety approach also need to be adapted, as these are the main factors of tension identified by the survey. The publication of ASN Decision 2019-DC-660 has extended the scope of the quality manager to include imaging in several centers.PMID:37482462 | DOI:10.1016/j.canrad.2023.06.009 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - July 23, 2023 Category: Cancer & Oncology Authors: G Brusadin S Cucchiaro S Nardin É Leroy Source Type: research
